Repeat Insult Patch Test of Skin Irritation/Sensitization for Cetaphil Daily Facial Cleanser
Launched by GALDERMA R&D · Jun 26, 2013
Trial Information
Current as of May 30, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Not currently under a doctor's care
- • Free of dermatological or systemic disorder which would interfere with the results
- • Free of any acute or chronic disease
- • Will complete a preliminary medical history form and are in general good health
- • Can read, understand, and sign informed consent
- Exclusion Criteria:
- • Under 18 years old
- • Currently under doctor's care
- • Currently taking any medication
- • History of acute or chronic disease
- • Diagnosed with chronic skin allergies
- • Pregnant or lactating
About Galderma R&D
Galderma R&D is a global leader in dermatological innovation, dedicated to advancing skin health through rigorous research and development. With a strong commitment to scientific excellence, Galderma focuses on creating effective and safe treatments for a variety of skin conditions, including acne, rosacea, and psoriasis. The organization collaborates with healthcare professionals and researchers worldwide to bring cutting-edge solutions to market, ensuring that patients receive the highest quality care. Through its extensive clinical trials and commitment to regulatory compliance, Galderma R&D strives to enhance the understanding of dermatological diseases and improve patient outcomes.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
New City, New York, United States
Patients applied
Trial Officials
Mayya Tastene, MD
Principal Investigator
AMA Laboratories
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials